The therapeutic efficacy of curcumin nanoemulsion versus Spiramycin in Toxoplasma gondii (ME49 strain) chronically infected mice
Rageh, E., M Abaza, S., El-Gayar, E., Barakat, A., Alabbassy, M. (2022). The therapeutic efficacy of curcumin nanoemulsion versus Spiramycin in Toxoplasma gondii (ME49 strain) chronically infected mice. EKB Journal Management System, 15(2), 174-180. doi: 10.21608/puj.2022.149674.1175
Eman Rageh; Sherif M Abaza; Eman El-Gayar; Ashraf Barakat; Maha Alabbassy. "The therapeutic efficacy of curcumin nanoemulsion versus Spiramycin in Toxoplasma gondii (ME49 strain) chronically infected mice". EKB Journal Management System, 15, 2, 2022, 174-180. doi: 10.21608/puj.2022.149674.1175
Rageh, E., M Abaza, S., El-Gayar, E., Barakat, A., Alabbassy, M. (2022). 'The therapeutic efficacy of curcumin nanoemulsion versus Spiramycin in Toxoplasma gondii (ME49 strain) chronically infected mice', EKB Journal Management System, 15(2), pp. 174-180. doi: 10.21608/puj.2022.149674.1175
Rageh, E., M Abaza, S., El-Gayar, E., Barakat, A., Alabbassy, M. The therapeutic efficacy of curcumin nanoemulsion versus Spiramycin in Toxoplasma gondii (ME49 strain) chronically infected mice. EKB Journal Management System, 2022; 15(2): 174-180. doi: 10.21608/puj.2022.149674.1175

The therapeutic efficacy of curcumin nanoemulsion versus Spiramycin in Toxoplasma gondii (ME49 strain) chronically infected mice

Parasitologists United Journal
Article 6, Volume 15, Issue 2, August 2022, Page 174-180  XML PDF (380.8 K)
Document Type: Original Article
DOI: 10.21608/puj.2022.149674.1175
View on SCiNiTO View on SCiNiTO
Authors
Eman Rageh1; Sherif M Abaza2; Eman El-Gayar3; Ashraf Barakat4; Maha Alabbassy email 2
1Departments of Medical Parasitology , Faculty of Medicine, Suez Canal University, Ismailia,
2Departments of Medical Parasitology, Faculty of Medicine, Suez Canal University, Ismailia
3Departments of Medical Parasitology,Faculty of Medicine, Suez Canal University, Ismailia
4Departments of Zoonotic Diseases ,Faculty of Medicine, National Research Center, Giza , Egypt
Abstract
Background: Previously, we showed that curcumin (CUR) nanoemulsion exhibited a promising
prophylactic effect on acute toxoplasmosis, and decreased parasite burden. Scanning electron microscopy
(SEM) of the peritoneal exudates showed deformed tachyzoites in both prophylactic and treated subgroups.
Objective: The present study is designed to evaluate the therapeutic effect of CUR nanoemulsion compared
to that of Spiramycin on T. gondii type II, ME49 strain causing chronic toxoplasmosis in experimentally
infected mice.
Material and Methods: This case-control experimental study included 30 Swiss albino mice, divided into
three equal groups. All mice were infected with avirulent ME49 strain to induce chronic toxoplasmosis.
The study included group I (infected non-treated), II (infected treated with CUR nanoemulsion), and III
(infected and treated with Spiramycin). The assessment parameters included estimation of the mortality
rate, and parasite burden (cyst number and size) in livers and spleens impression smears, and in brains
homogenates.
Results: The mortality rate was 40% in the infected non-treated group with no mortality in all treated
mice. There was a significant decrease of cyst number and size in livers, spleens, and brains of both treated
groups as compared to the infected non-treated mice.
Conclusion: It was concluded that CUR nanoemulsion had a promising therapeutic effect on chronic
toxoplasmosis.
Keywords
chronic toxoplasmosis; curcumin; experimental study; nanoemulsion; Spiramycin
Statistics
Article View: 283
PDF Download: 605